With the ink on their $25M Astel­las deal still dry­ing, Aquinox shares get blast­ed on PhI­II fail­ure

Just weeks af­ter Astel­las agreed to pay Aquinox Phar­ma­ceu­ti­cals $25 mil­lion up­front for Asian rights to their lead drug rosip­tor, the lit­tle biotech says their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER